Commercialization of Human Visceral Adipocytes

Information

  • Research Project
  • 7121195
  • ApplicationId
    7121195
  • Core Project Number
    R44DK065323
  • Full Project Number
    5R44DK065323-03
  • Serial Number
    65323
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/2003 - 21 years ago
  • Project End Date
    8/31/2007 - 17 years ago
  • Program Officer Name
    LUNDBERG, MARTHA
  • Budget Start Date
    9/1/2006 - 18 years ago
  • Budget End Date
    8/31/2007 - 17 years ago
  • Fiscal Year
    2006
  • Support Year
    3
  • Suffix
  • Award Notice Date
    8/7/2006 - 18 years ago
Organizations

Commercialization of Human Visceral Adipocytes

[unreadable] DESCRIPTION (provided by applicant): The US is experiencing an epidemic rise in obesity and related co-morbidities such as type II diabetes. Epidemiological studies demonstrate that these co-morbidities are specifically correlated with visceral (intra-abdominal) fat deposition. To elucidate this association, a fully characterized and performance tested cultured human adipocyte cell system must be made available to researchers. The goal of the proposed work is to develop a commercially accessible, novel, well characterized cultured human visceral adipocyte cell system. Preliminary data indicate visceral adipocytes are distinct from subcutaneous adipocytes, requiring individualized culturing and assaying techniques. Phase II has three specific aims. I. Establish a protocol for differentiation of visceral preadipocytes into adipocytes. II. Develop a suite of assays necessary to provide quality control tests for the cultured cells. The assays will also be offered as a commercial contract research service utilizing the visceral cell system. III. Perform expression profiling of primary and cultured visceral adipocytes and preadipocytes in order to validate the cultured cell system. The completion of the research will result in a commercially accessible, performance tested, fully validated cultured human visceral adipocyte cell system. Availability of this system will open the door for large scale screening in cultured human visceral cells, provide a better understanding of the roles visceral adipose plays in disease development and provide a faster and less expensive path to drug development. [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R44
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    487868
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:487868\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ZEN-BIO, INC.
  • Organization Department
  • Organization DUNS
    799863261
  • Organization City
    RTP
  • Organization State
    NC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    27709
  • Organization District
    UNITED STATES